Cabazitaxel

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Cabazitaxel
Cabazitaxel.png
Clinical data
Trade names Jevtana
AHFS/Drugs.com Consumer Drug Information
MedlinePlus a611009
License data
Pregnancy
category
  • US: D (Evidence of risk)
Routes of
administration
Intravenous
ATC code
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
ECHA InfoCard 100.205.741 Edit this at Wikidata
Chemical and physical data
Formula C45H57NO14
Molar mass 835.93 g/mol
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

Cabazitaxel (previously XRP-6258, trade name Jevtana) is a semi-synthetic derivative of a natural taxoid.[1] It was developed by Sanofi-Aventis and was approved by the U.S. FDA for the treatment of hormone-refractory prostate cancer on June 17, 2010. It is a microtubule inhibitor, and the fourth taxane to be approved as a cancer therapy.[2][unreliable source?]

Cabazitaxel in combination with prednisone is a treatment option for hormone-refractory prostate cancer following docetaxel-based treatment.

Clinical trials[edit]

In a phase III trial with 755 men for the treatment of castration-resistant prostate cancer, median survival was 15.1 months for patients receiving cabazitaxel versus 12.7 months for patients receiving mitoxantrone. Cabazitaxel was associated with more grade 3–4 neutropenia (81.7%) than mitoxantrone (58%).[3]

See also[edit]

References[edit]

External links[edit]